Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraSure suit, sales

This article was originally published in The Tan Sheet

Executive Summary

Additional expenses associated with Schering-Plough patent suit "will make it difficult to achieve full-year profitability in fiscal 2004," OraSure CEO Douglas Michels says Aug. 3. The Bethlehem, Penn.-based firm recently filed suit against Schering for infringement of several cryosurgical wart removal patents (1"The Tan Sheet" Aug. 2, 2004, p. 11). OraSure's total revenues increased 37% to $13.2 mil. in the second quarter (ended June 30) on the strength of Freeze Off and Histofreezer sales...

You may also be interested in...



Orasure Aims To Freeze Schering Wart Removal Product In Patent Suit

Schering-Plough Healthcare Products' Dr. Scholl's Freeze Away infringes on three of OraSure Technologies' cryosurgical wart removal patents, OraSure alleges in a July 23 suit

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Topics

UsernamePublicRestriction

Register

PS097147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel